상세 보기

Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTIPD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study

Rha, S. Y.;
Bae, W. K.;
Kim, C.;
Oh, S. Y.;
Lee, H. W.;
... Park, K. H.;
외 14명

제목: Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTIPD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study

저자: Rha, S. Y.; Bae, W. K.; Kim, C.; Oh, S. Y.; Lee, H. W.; Park, K.; Mar, N.; Kichenadasse, G.; Ha, H. K.; Pachynski, R.; Park, I.; Park, K. H.; Kim, S. H.; Folefac, E.; Mathias, M. D.; Seebach, F.; Ma, S.; Carranza, L.; Beom, S-H.; Merchan, J. R.

DOI: 10.1016/j.annonc.2023.09.1115

발행일: 2023-10

학회명: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)

개최지: Barcelona, SPAIN

개최국가: 스페인

학회 개최일: 2023-10-20 ~ 2023-10-24

언어: ENG